Anti-tau therapies, including monoclonal antibodies, AAV vectors, and small molecules, are currently being studied, with some already in clinical trials for Alzheimer’s disease, and could potentially be adapted for TBI studies. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.